|
|
1649422974 April 08, 2022 |
BLU-945 |
American Association for Cancer Research (AACR) Annual Meeting |
|
Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA in the phase 1/2 SYMPHONY study
|
|
|
1649422912 April 08, 2022 |
BLU-701 & BLU-945 |
American Association for Cancer Research (AACR) Annual Meeting |
|
Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC
|
|
|
1649422898 April 08, 2022 |
BLU-451 |
American Association for Cancer Research (AACR) Annual Meeting |
|
LNG-451 (BLU-451), a potent inhibitor of EGFR exon 20 insertion mutations with high CNS exposure
|
|
|
1649422883 April 08, 2022 |
BLU-222 |
American Association for Cancer Research (AACR) Annual Meeting |
|
BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models
|
|
|
1649422872 April 08, 2022 |
Research |
American Association for Cancer Research (AACR) Annual Meeting |
|
Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of imatinib-resistant GIST
|
|
|
1649422870 April 08, 2022 |
BLU-451 |
American Association for Cancer Research (AACR) Annual Meeting |
|
LNG-451 (BLU-451) is a potent, CNS-penetrant, wild-type EGFR sparing inhibitor of EGFR exon 20 insertion mutations
|
|
|
1646052340 February 28, 2022 |
HEOR - SM |
American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting |
|
Comorbidity and Disability in Medicare Beneficiaries Newly Diagnosed with Non-Advanced Systemic Mastocytosis
|
|
|
1646052312 February 28, 2022 |
HEOR - SM |
American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting |
|
Utility of a Validated Disease-Specific Measure to Assess Symptomology in Patients with Indolent Systemic Mastocytosis (ISM)
|
|
|
1646052311 February 28, 2022 |
BLU-263 |
American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting |
|
A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome (TiP)
|
|
|
1645879535 February 26, 2022 |
HEOR - SM |
American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting |
|
Disease Symptomology, Quality of Life (QoL), and Employment Status Among Patients with Systemic Mastocytosis (SM)
|
|
|
1643360826 January 28, 2022 |
BLU-701 & BLU-945 |
British Thoracic Oncology Group (BTOG) Annual Conference |
|
BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer driven by EGFR mutations
|
|
|
1639299900 December 12, 2021 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Efficacy of Avapritinib in Patients With Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses From the Phase 2 Open-Label, Single-Arm, PATHFINDER Study
|
|
|
1639238702 December 11, 2021 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Effective Control of Advanced Systemic Mastocytosis with Avapritinib: Mutational Analysis from the EXPLORER Clinical Study
|
|
|
1638806695 December 06, 2021 |
Avapritinib - SM |
Nature Medicine |
|
Efficacy and Safety of Avapritinib in Advanced Systemic Mastocytosis: Interim Analysis of the Phase 2 PATHFINDER trial
|
|
|
1638806644 December 06, 2021 |
Avapritinib - SM |
Nature Medicine |
|
Safety and Efficacy of Avapritinib in Advanced Systemic Mastocytosis: the Phase 1 EXPLORER trial
|
|
|
1637350218 November 19, 2021 |
Avapritinib - GIST |
2021 Society for Neuro-Oncology Annual Meeting and Education Day |
|
A phase 1/2 study of avapritinib in pediatric patients with solid tumors dependent on KITor PDGFRA signaling
|
|
|
1625972401 July 11, 2021 |
Avapritinib - SM |
European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Annual Congress 2021 |
|
Avapritinib improves overall symptoms, skin lesions and quality of life in patients with advanced systemic mastocytosis in the PATHFINDER study
|
|
|
1623402340 June 11, 2021 |
Avapritinib - SM |
European Hematology Association (EHA) Virtual Congress |
|
Efficacy and safety of avapritinib in patients with advanced systemic mastocytosis: Interim results from the open-label, single-arm, phase 2 PATHFINDER study
|
|
|
1623316840 June 10, 2021 |
Avapritinib |
2021 Society for Neuro-Oncology (SNO) Pediatric Conference |
|
A phase 1/2, single-arm study to evaluate the safety, pharmacokinetics, and antitumor activity of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling
|
|
|
1623229664 June 09, 2021 |
Pralsetinib |
The Lancet Oncology |
|
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
|
|
|
1623229642 June 09, 2021 |
Pralsetinib |
The Lancet Diabetes and Endocrinology |
|
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
|
|
|
1622797336 June 04, 2021 |
Pralsetinib |
American Society for Clinical Oncology (ASCO) Annual Meeting |
|
Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: update from the ARROW trial
|
|
|
1622797320 June 04, 2021 |
Pralsetinib |
American Society of Clinical Oncology (ASCO) Annual Meeting |
|
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: update from the ARROW trial
|
|
|
1618150109 April 11, 2021 |
Avapritinib - SM |
American Association for Cancer Research (AACR) Annual Meeting |
|
PATHFINDER: Interim analysis of avapritinib in patients with Advanced Systemic Mastocytosis (AdvSM)
|
|
|
1618043459 April 10, 2021 |
BLU-222 |
American Association for Cancer Research (AACR) Annual Meeting |
|
Development of a selective CDK2-E inhibitor in CCNE-aberrant cancers
|
|
|
1618043457 April 10, 2021 |
BLU-852 |
American Association for Cancer Research (AACR) Annual Meeting |
|
MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models
|
|
|
1618043450 April 10, 2021 |
BLU-945 |
American Association for Cancer Research (AACR) Annual Meeting |
|
BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity, demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer
|
|
|
1618043435 April 10, 2021 |
BLU-701 |
American Association for Cancer Research (AACR) Annual Meeting |
|
BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC
|
|
|
1618043429 April 10, 2021 |
BLU-263 |
American Association for Cancer Research (AACR) Annual Meeting |
|
Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers
|
|
|
1618043402 April 10, 2021 |
Avapritinib - SM |
American Association for Cancer Research (AACR) Annual Meeting |
|
Changes in mast cell numbers and phenotype in patients with indolent systemic mastocytosis treated with avapritinib
|
|
|
1610790107 January 16, 2021 |
Avapritinib - GIST |
European Journal of Cancer |
|
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
|
|
|
1607335543 December 07, 2020 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
PIONEER Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis
|
|
|
1607335517 December 07, 2020 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Perceptions of Patient Disease Burden and Management Approaches of Systemic Mastocytosis (SM) By Healthcare Providers (HCPs): Results from the TouchStone SM Survey
|
|
|
1607335504 December 07, 2020 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Increased Detection of KIT D816V Mutation in Peripheral Blood Samples from Patients with Indolent Systemic Mastocytosis (ISM) in the Phase 2 PIONEER Study Using a High Sensitivity Droplet Digital (dd) PCR Assay Compared with Next Generation Sequencing (NGS)
|
|
|
1607260818 December 06, 2020 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study
|
|
|
1607162755 December 05, 2020 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Patient Reported Outcomes Among Systemic Mastocytosis (SM) Patients in Routine Clinical Practice: Results from the TouchStone Survey
|
|
|
1607162751 December 05, 2020 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Results from PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent Systemic Mastocytosis
|
|
|
1605104268 November 11, 2020 |
Avapritinib - GIST |
Connective Tissue Oncology Society (CTOS) Annual Meeting |
|
Avapritinib vs. Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST): Efficacy and Safety Data From Phase 3 VOYAGER Study
|
|
|
1602924933 October 17, 2020 |
Pralsetinib |
IASLC North America Conference on Lung Cancer |
|
Analysis of Resistance Mechanisms to Pralsetinib (BLU-667) in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
|
|
|
1600591101 September 20, 2020 |
Pralsetinib |
European Society for Medical Oncology (ESMO) Virtual Congress |
|
Results from the registrational phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients with advanced RET mutation-positive medullary thyroid cancer
|
|
|
1600419622 September 18, 2020 |
Avapritinib - GIST |
European Society for Medical Oncology (ESMO) Virtual Congress |
|
Long-term efficacy, tolerability and overall survival in patients with unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumor treated with avapritinib: NAVIGATOR phase 1 trial update
|
|
|
1600333219 September 17, 2020 |
Avapritinib - GIST |
European Society for Medical Oncology (ESMO) Virtual Congress |
|
Clinical Efficacy Comparison of Avapritinib With Other Tyrosine Kinase Inhibitors (TKIs) in Gastrointestinal Stromal Tumors (GIST) With PDGFRA D842V Mutation: A Retrospective Analysis of Clinical Trial and Real-World Data
|
|
|
1600330034 September 17, 2020 |
BLU-945 |
European Society for Medical Oncology (ESMO) Virtual Congress |
|
BLU-945, a highly potent and selective 4th-generation EGFR TKI for the treatment of EGFR+/T790M/C797S resistant NSCLC
|
|
|
1593456441 June 29, 2020 |
Avapritinib - GIST |
The Lancet Oncology |
|
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
|
|
|
1591929312 June 12, 2020 |
Avapritinib - SM |
Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress |
|
Results from PIONEER: a randomized, double-blind, placebo-controlled, Phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM)
|
|
|
1591929310 June 12, 2020 |
Avapritinib - SM |
Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress |
|
Avapritinib induces responses in patients with advanced systemic mastocytosis (AdvSM), regardless of prior midostaurin therapy
|
|
|
1591434304 June 06, 2020 |
Avapritinib - SM |
European Academy of Allergy and Clinical Immunology (EAACI) 2020 Digital Congress |
|
Avapritinib reduces cutaneous symptoms and mast cell burden in patients with indolent systemic mastocytosis in the PIONEER study
|
|
|
1590912102 May 31, 2020 |
Pralsetinib |
American Society of Clinical Oncology (ASCO) Virtual Scientific Program |
|
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors
|
|
|
1590739456 May 29, 2020 |
Pralsetinib |
American Society of Clinical Oncology (ASCO) Virtual Scientific Program |
|
AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET Fusion+ Advanced/Metastatic Non-Small-Cell Lung Cancer (NSCLC)
|
|
|
1590739434 May 29, 2020 |
Pralsetinib |
American Society of Clinical Oncology (ASCO) Virtual Scientific Program |
|
Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer (NSCLC)
|
|
|
1584342045 March 16, 2020 |
Avapritinib - SM |
American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Oral Abstracts, Case Reports and Poster Sessions |
|
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
|
|
|
1575795946 December 08, 2019 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
|
|
|
1573772438 November 14, 2019 |
Avapritinib - GIST |
Connective Tissue Oncology Society (CTOS) Annual Meeting |
|
Clinical Response to Avapritinib by RECIST and Choi Criteria in ≥ 4th Line and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
|
|
|
1573702237 November 14, 2019 |
Avapritinib - GIST |
Connective Tissue Oncology Society (CTOS) Annual Meeting |
|
Avapritinib for the Treatment of GIST: Analysis of Efficacy, Safety, and Patient Management Strategies at the Recommended Phase 2 Dose
|
|
|
1573137683 November 07, 2019 |
Avapritinib - SM |
ISPOR Europe |
|
Psychometric Evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) in patients with Advanced Systemic Mastocytosis
|
|
|
1573137287 November 07, 2019 |
Avapritinib - SM |
ISPOR Europe |
|
Psychometric Performance of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF)
|
|
|
1569920764 October 01, 2019 |
Fisogatinib |
Cancer Discovery |
|
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
|
|
|
1569920650 October 01, 2019 |
Fisogatinib |
Cancer Discovery |
|
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
|
|
|
1569823542 September 30, 2019 |
Pralsetinib |
European Society for Medical Oncology (ESMO) Annual Meeting |
|
Treatment With Pralsetinib (BLU-667), a Potent and Selective RET Inhibitor, Provides Rapid Clearance of ctDNA in Patients With RET-Altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
|
|
|
1569155420 September 22, 2019 |
BLU-782 |
American Society for Bone and Mineral Research (ASMBR) Annual Meeting |
|
A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)
|
|
|
1568023113 September 09, 2019 |
Pralsetinib |
IASLC World Conference on Lung Cancer |
|
Pralsetinib (BLU-667) demonstrates robust activity in RET-fusion-driven intracranial tumor models
|
|
|
1560579358 June 15, 2019 |
Avapritinib - SM |
European Hematology Association (EHA) Annual Meeting |
|
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients (pts) with Advanced Systemic Mastocytosis (AdvSM)
|
|
|
1559552740 June 03, 2019 |
Pralsetinib |
American Society of Clinical Oncology (ASCO) Annual Meeting |
|
Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-Fusion+ Non-small Cell Lung Cancer
|
|
|
1559398538 June 01, 2019 |
Pralsetinib |
American Society of Clinical Oncology (ASCO) Annual Meeting |
|
Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-altered Thyroid Cancers
|
|
|
1559379949 June 01, 2019 |
Avapritinib - GIST |
American Society of Clinical Oncology (ASCO) Annual Meeting |
|
Clinical Activity of Avapritinib in ≥4th Line (4L+) and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
|
|
|
1553970136 March 30, 2019 |
Pralsetinib |
American Association for Cancer Research (AACR) Annual Meeting |
|
Discovery of BLU-667 for RET-driven cancers
|
|
|
1543789289 December 02, 2018 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)
|
|
|
1542320453 November 15, 2018 |
Avapritinib - GIST |
Connective Tissue Oncology Society (CTOS) Annual Meeting |
|
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA (oral presentation)
|
|
|
1540246817 October 22, 2018 |
Avapritinib - GIST |
European Society for Medical Oncology (ESMO) Annual Meeting |
|
Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib (poster presentation)
|
|
|
1540246775 October 22, 2018 |
Avapritinib - GIST |
European Society for Medical Oncology (ESMO) Annual Meeting |
|
An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (poster presentation)
|
|
|
1538864323 October 06, 2018 |
Pralsetinib |
American Thyroid Association (ATA) Annual Meeting |
|
Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study (oral presentation)
|
|
|
1538432296 October 01, 2018 |
Avapritinib - GIST |
Clinical Cancer Research |
|
Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors
|
|
|
1538345823 September 30, 2018 |
BLU-782 |
American Society for Bone and Mineral Research (ASBMR) Annual Meeting |
|
BLU-782: A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
|
|
|
1538000121 September 26, 2018 |
Pralsetinib |
IASLC World Conference on Lung Cancer |
|
Activity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (oral presentation)
|
|
|
1538000089 September 26, 2018 |
Pralsetinib |
Cancer Discovery |
|
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion
|
|
|
1529100833 June 15, 2018 |
Avapritinib - SM |
European Hematology Association (EHA) Annual Meeting |
|
Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1 Study (poster presentation)
|
|
|
1523830394 April 15, 2018 |
Pralsetinib |
American Association for Cancer Research (AACR) Annual Meeting |
|
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors (oral presentation)
|
|
|
1523830353 April 15, 2018 |
Pralsetinib |
Cancer Discovery |
|
Precision targeted therapy with BLU-667 for RET-driven cancers
|
|
|
1512943899 December 10, 2017 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (plenary oral presentation)
|
|
|
1510351812 November 10, 2017 |
Avapritinib - GIST |
Connective Tissue Oncology Society (CTOS) Annual Meeting |
|
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) (oral presentation)
|
|
|
1509574157 November 01, 2017 |
Avapritinib |
Science Translational Medicine |
|
A precision therapy against cancers driven by KIT/PDGFRA mutations
|
|
|
1509314866 October 29, 2017 |
Pralsetinib |
Molecular Targets and Cancer Therapeutics (AACR – NCI – EORTC) |
|
BLU-667 is a Potent and Highly Selective RET Inhibitor Being Developed for RET-Driven Cancers
|
|
|
1505685990 September 17, 2017 |
Fisogatinib |
International Liver Cancer Association (ILCA) Annual Conference |
|
(Clinical activity Of BLU-554, a potent, highly-selective FGFR4 inhibitor in advanced HCC with FGFR4 pathway activation (oral presentation)
|
|
|
1505081139 September 10, 2017 |
Fisogatinib |
European Society for Medical Oncology (ESMO) Annual Meeting |
|
Phase 1 Safety and Clinical Activity of BLU-554 in advanced hepatocellular carcinoma (oral presentation)
|
|
|
1501452295 July 30, 2017 |
Pralsetinib |
World Congress on Thyroid Cancer |
|
BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers
|
|
|
1496700240 June 05, 2017 |
Avapritinib - GIST |
American Society of Clinical Oncology (ASCO) Annual Meeting |
|
Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
|
|
|
1491170553 April 02, 2017 |
Avapritinib - GIST |
American Association for Cancer Research (AACR) Annual Meeting |
|
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
|
|
|
1491170447 April 02, 2017 |
Avapritinib - SM |
American Association for Cancer Research (AACR) Annual Meeting |
|
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
|
|
|
1480888795 December 04, 2016 |
Avapritinib - SM |
American Society of Hematology (ASH) Annual Meeting |
|
Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (oral presentation)
|
|
|
1480629552 December 01, 2016 |
Avapritinib - GIST |
EORTC – NCI – AACR Molecular Targets and Cancer Therapeutics Symposium |
|
Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
|
|
|
1480456639 November 29, 2016 |
Fisogatinib |
Molecular Targets and Cancer Therapeutics (EORTC – NCI – AACR) |
|
First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation (poster presentation)
|
|
|
1461016563 April 18, 2016 |
Pralsetinib |
American Association for Cancer Research (AACR) Annual Meeting |
|
The development of Potent and Selective RET inhibitors
|
|
|
1430516121 May 01, 2015 |
Research |
Journal of Clinical Investigation |
|
Targeting cancer with kinase inhibitors
|
|
|
1426541525 March 16, 2015 |
Fisogatinib |
Cancer Discovery |
|
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
|
|
|
1411162202 September 19, 2014 |
Research |
Nature Communications |
|
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes
|
|
|
1410384400 September 10, 2014 |
Research |
Nature Communications |
|
The landscape of kinase fusions in cancer
|
